Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

e Webcast will be available until midnight April 30, 2008.

Upcoming Events

Genzyme will host a conference call on July 23, 2008 at 11:00 a.m. Eastern to discuss financial results for the second quarter of 2008. To participate in the call, please dial 773-799-3828 and refer to pass code "Genzyme." A replay of this call will be available by dialing 402-998-1342. This call will also be Webcast live on the investor events section of http://www.genzyme.com. Replays of the call and the Webcast will be available until midnight on July 30, 2008.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Contact:

Bo Piela Patrick Flanigan

(617) 768-6579 (617) 768-6563

GENZYME CORPORATION (GENZ)

Consolidated Statements of Operations

(Unaudited, amounts in thousands, Three Months Ended

except per share amounts) March 31,

2008 2007

Total revenues $1,100,061 $883,183

Operating costs and expenses:

Cost of products and services sold (1) 272,313 202,463

Selling, general and administrative (1) 318,386 269,021

Research and development (1,2) 262,797 166,120

Amortization of intangibles 55,658 50,017

Total operating costs and expenses 909,154 687,621

Operating income (loss) 190,907 195,562

Other income (expenses):

Equity in income of equi
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
(Date:12/19/2014)... -- Decision Resources Group finds that the Latin American ... compound annual growth rate through 2023. This is primarily ... increasing adoption of dental implants. Growing aesthetic consciousness in ... demand for dental biomaterials because they can improve the ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... In contrast to traditional LED lights where the ... uses proprietary LED technology to incorporate their spectra in ... is critical in low proximity installations. The Valoya L-series ... lifetime which is up to four times longer than ... cost was clearly higher when compared to traditional fluorescent ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... Palatin,Technologies, Inc. (Amex: PTN ) announced today ... PL-3994, a novel, long-acting natriuretic peptide,receptor A (NPRA) ... heart failure (CHF). The Phase I trial was ... 26 healthy volunteers who received the medication or ...
... Cepheid (Nasdaq:,CPHD) will present at Cowen and ... 10:15 a.m. ET at The Boston Marriott Copley ... will provide a corporate overview., The webcast, ... Cepheid,s Web site at http://www.cepheid.com under ...
... March 10 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... its,registrational bioequivalence clinical study of ANX-530 (vinorelbine,emulsion) will ... American Society,of Clinical Oncology (ASCO) in connection with ... - June 3, 2008 in Chicago, IL. The ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4Cepheid to Present at Cowen and Company's 28th Annual Healthcare Conference 2Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology 2Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology 3
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... C-Labs LLC, a leading provider of remote ... today announced the appointment of John Traynor ... strategic advisor to the firm, Mr. Traynor will now ... based out of the C-Labs office in ... Muench , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... Nov. 17, 2014   News ... collaborate to develop The Partners Data Lake, an ... Partners Data Lake will allow researcher and clinicians ... treatment and the lives of patients , ... clinical activities across the Partners system, breaking down ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... brain and, more specifically, how nerve cells form billions of contacts ... scientific mystery. , A team headed by Drs. Robin Hiesinger and ... unraveled a piece of that puzzle by finding a gene that ... work appears today in the journal Neuron. , "We were surprised ...
... virus at Churchill Downs, home of the Kentucky Derby, ... that vaccines containing weakened live viruses, called modified live ... horse herpes than other more widely used vaccines. , ... been in use for decades, has proven to be ...
... study has found that a protein known for its ... of initiating DNA repair. The study, published in the ... targets for treatment of cancer. , Ze'ev Ronai, Ph.D., ... colleagues found that the protein ATF2 ("Activating Transcription Factor-2") ...
Cached Biology News:Live vaccines more effective against horse herpes virus 2Live vaccines more effective against horse herpes virus 3New understanding of DNA repair may pave way to cancer treatments 2
... be induced prior to DNA purification increasing ... of single-copy BACs with the high yields ... The kits provide the linearized vector and ... system) necessary to create a 10X human ...
... content or with significant secondary structure are ... subjected to PCR result in little or ... be increased by the addition of enhancing ... an effective PCR enhancer for GC-rich templates., ...
...
... EPICENTREs patented MasterAmp™ 10X PCR Enhancer ... and allows improved sensitivity and specificity ... Using MasterAmp PCR Enhancer in PCR ... DNA melting, increases enzyme?s thermal stability, ...
Biology Products: